Sugi Predict

Sugi Predict / Targets / GIPR

GIPR

Gastric inhibitory polypeptide receptor · P48546 · GIPR on Sugi Atlas →

16,288 patent compounds predicted against GIPR, 10,990 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL825813 SCHEMBL825813 1.00 15/20
SCHEMBL827984 SCHEMBL827984 1.00 15/20
SCHEMBL1966239 SCHEMBL1966239 1.00 15/20
SCHEMBL826673 SCHEMBL826673 1.00 14/20
Mk-0893 Mk-0893 (SCHEMBL675777) 1.00 13/20
SCHEMBL928959 SCHEMBL928959 0.87 13/20
SCHEMBL926751 SCHEMBL926751 0.82 13/20
SCHEMBL675778 SCHEMBL675778 0.71 13/20
SCHEMBL1100877 SCHEMBL1100877 0.51 12/20
SCHEMBL2254559 SCHEMBL2254559 0.78 8/20
SCHEMBL2249840 SCHEMBL2249840 0.75 8/20
SCHEMBL926680 SCHEMBL926680 0.65 8/20
SCHEMBL1895066 SCHEMBL1895066 0.54 8/20
SCHEMBL1895068 SCHEMBL1895068 0.54 8/20
SCHEMBL2249206 SCHEMBL2249206 0.53 8/20
SCHEMBL2251811 SCHEMBL2251811 0.52 8/20
SCHEMBL2251280 SCHEMBL2251280 0.51 8/20
SCHEMBL2249887 SCHEMBL2249887 0.82 7/20
SCHEMBL2251873 SCHEMBL2251873 0.77 7/20
SCHEMBL2250246 SCHEMBL2250246 0.76 7/20

Clinical trials — most relevant to GIPR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients PHASE4COMPLETED
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET PHASE2/PHASE3COMPLETED
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET PHASE2/PHASE3COMPLETED
Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 Diabetes PHASE3UNKNOWN
A Research Study of VCT220 in Adult Chinese Participants With Obesity PHASE3ACTIVE_NOT_RECRUITING
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) PHASE3COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes PHASE3COMPLETED
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity PHASE2RECRUITING
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
Bariatric Surgery Combined With GLP-1 Receptor Agonists Study PHASE1/PHASE2RECRUITING
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose PHASE1COMPLETED
Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4) nanCOMPLETED
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake nanCOMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD nanRECRUITING
Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores nanNOT_YET_RECRUITING
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist nanCOMPLETED
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function nanCOMPLETED
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs nanACTIVE_NOT_RECRUITING
GIP Receptor Antagonist Studies in Humans nanCOMPLETED
The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism nanCOMPLETED
A Consumer Health Study Evaluating the Impact of Pivit on Weight Loss and Appetite in Overweight Individuals nanACTIVE_NOT_RECRUITING
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity nanNOT_YET_RECRUITING
Dietary Carbohydrate and GERD in Veterans nanCOMPLETED
Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus nanCOMPLETED
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes nanCOMPLETED
Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment nanRECRUITING
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GIPR binder may also engage these)

ProteinNameSimilarity
P43219 — 1.000 P43219 →
Q0P543 — 1.000 Q0P543 →
P43218 — 1.000 P43218 →
GCGR Glucagon receptor 1.000 landscape →
A0A2Z2U4G9 — 1.000 A0A2Z2U4G9 →
P34999 — 1.000 P34999 →
Q61606 — 1.000 Q61606 →
O35659 — 0.999 O35659 →
GLP1R Glucagon-like peptide 1 receptor 0.996 landscape →
O46502 — 0.995 O46502 →
Q28992 — 0.995 Q28992 →
Q5FWI2 — 0.994 Q5FWI2 →
P30083 — 0.993 P30083 →
Q02644 — 0.993 Q02644 →
P32301 — 0.992 P32301 →
GHRHR Growth hormone-releasing hormone receptor 0.992 landscape →
VIPR1 Vasoactive intestinal polypeptide receptor 1 0.992 landscape →
P23811 — 0.991 P23811 →
VIPR2 Vasoactive intestinal polypeptide receptor 2 0.991 landscape →
P97751 — 0.991 P97751 →
P30082 — 0.991 P30082 →
P32082 — 0.990 P32082 →
Q5IXF8 — 0.990 Q5IXF8 →
Q5RAQ1 — 0.988 Q5RAQ1 →
O95838 — 0.988 O95838 →
SCTR Secretin receptor 0.988 landscape →
Q9Z0W0 — 0.988 Q9Z0W0 →
Q1LZF7 — 0.987 Q1LZF7 →
P41588 — 0.987 P41588 →
P25117 — 0.984 P25117 →